Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Cell-based Screening Kit for Anti-human 4-1BB Antibody (Human CD16a (158V) High Expression)

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Product Specifications

Background

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

CAS Number

9007-83-4

Origin Species

Human

Target

4-1BB & CD16a

Applications

Screen for Anti-human 4-1BB antibodies whether in a CD16a (158V)-dependent manner to strengthen the agonistic activity

Format

Solid

Shipping Conditions

Dry ice

Storage Conditions

Frozen in liquid nitrogen

More Discoveries

Explore Other Products

Browse additional items from our catalog

ARHGDIA (Rho GDP-dissociation Inhibitor 1, Rho GDI 1, Rho-GDI alpha, GDIA1) (PE)
123495-PE 100 µL

ARHGDIA (Rho GDP-dissociation Inhibitor 1, Rho GDI 1, Rho-GDI alpha, GDIA1) (PE)

Sign In for Pricing
View Details
Mab to Influenza B NP
MBS313779-01 1 mg

Mab to Influenza B NP

Sign In for Pricing
View Details
Mab to Influenza B NP
MBS313779-02 5x 1 mg

Mab to Influenza B NP

Sign In for Pricing
View Details
Fluralaner Impurity 63
RM-F101063-01 10 mg

Fluralaner Impurity 63

Sign In for Pricing
View Details
Fluralaner Impurity 63
RM-F101063-02 25 mg

Fluralaner Impurity 63

Sign In for Pricing
View Details
Fluralaner Impurity 63
RM-F101063-03 50 mg

Fluralaner Impurity 63

Sign In for Pricing
View Details